1. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr [Comparative Study Evaluation Studies Research Support, Non-U.S. Gov’t]. 2002;141(2):191–7.
2. Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int [Research Support, U.S. Gov’t, P.H.S.]. 2002;62(2):648–53.
3. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. New Engl J Med [Research Support, Non-U.S. Gov’t]. 2004; 350(26):2654–62.
4. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int [Consensus Development Conference]. 2006;69(11):1945–53.
5. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int [Research Support, N.I.H., Extramural]. 2011;79(12):1370–8.